BeyondSpring (NASDAQ:BYSI) Releases Earnings Results

BeyondSpring (NASDAQ:BYSI) released its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, FiscalAI reports.

BeyondSpring Price Performance

BYSI stock opened at $1.68 on Thursday. BeyondSpring has a 1 year low of $0.98 and a 1 year high of $3.44. The company has a market cap of $67.75 million, a P/E ratio of -11.20 and a beta of 0.56. The stock’s fifty day moving average price is $1.52 and its 200-day moving average price is $1.75.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned about 0.57% of BeyondSpring as of its most recent filing with the SEC. Hedge funds and other institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.